Date: February 12, 2025 FDA Approves Adcetris Overview The FDA has approved a new combination therapy for adults with relapsed…
Browsing: Lymphoma
… The field of oncology is witnessing a paradigm shift in the treatment of lymphomas, fueled by the emergence of…
On March 7, 2024, the Food and Drug Administration (FDA) granted accelerated approval to zanubrutinib, marketed as Brukinsa by BeiGene…
The FDA granted Priority Review of the supplemental Biologics License Application (sBLA) for epcoritamab-bysp. This subcutaneously administered T-cell engaging bispecific…
In 2024, CAR T-cell therapy continues to transform the landscape of treatment for hematologic malignancies, including multiple myeloma and various…
The full Video OnDemand is now available! This live, virtual, interactive patient education event includes presentations and panel discussions covering…
In the groundbreaking study conducted by Bruce Feinberg,DO, Chief Medical Officer at Cardinal Health, the focus is on investigating the…
Under the lights of ASH 2023, the microphone poised to capture insights, Dr. Lorenzo Falchi, a medical doctor and lymphoma…
By. Ash Alizadeh, MD Date: 12/13/2023 At ASH 2023, Dr. Ash Alizadeh, a distinguished medical doctor and professor of medicine…
By: Allen Wilbanks Date: October 03, 2023 Julie Vose, MD, a respected expert in the field of lymphoma, began her…
By: Allen WilbanksDate: October 02, 2023 In a comprehensive discussion led by the esteemed Swami Lyer, MD, the focus centered…
By: Allen Wilbanks Date: September 28/2023 Paolo Strati, MD, an assistant professor at the Anderson Cancer Center in Houston, Texas, delivered…
By: Allen Wilbanks Date: September 27,2023 In a recent presentation, Elizabeth Brem, MD shared her perspective on the utilization of minimal…
By: Allen Wilbanks Date: September 27 /2023 John Leonard, MD, a prominent figure in the field of oncology, delivered a…
Elizabeth Brem , MD discusses the design and outcomes of the study referred to as 1826. The study aimed to…
Brexucabtagene autoleucel (Tecartus) is a ground-breaking CAR T-cell therapy for the treatment of relapsed or refractory mantle cell lymphoma. The…
Swetha Kambhampati, MD from the City of Hope talks about the ASCO 2023 abstract about Mantle Cell Lymphoma Real-World Outcomes of…
iFrame is not supported! Breyanzi: CAR T-cell Therapy Gets Positive CHMP Opinion for R/R Large B-Cell Lymphoma Manali Kamdar MD…
Manali Kamdar, MD from University of Colorado Bristol Myers Squibb has received a positive opinion from the European Medicines Agency’s…
Polatuzumab Vedotin: How can the POLARIX trial help us comprehend DLBCL? Connor Johnson MD By P. Connor Johnson, MD My…
Tafasitamab: Final Results of Five-Year Safety and Efficacy Study (Phase II L-MIND) Prof. Kalakonda By Professor Nagesh Kalakonda Thank you…
Chimeric Antigen Receptor T-Cell Therapy: A Longitudinal Study Conner Johnson MD By Conner Johnson, MD Chimeric antigen receptor (CAR) T-cell…
Odronextamab: Promising Results in Treating Relapsed/Refractory Follicular Lymphoma: Findings from Phase II Study ELM-2 Tae Min Kim MD By Tae…
How effective is mosunetuzumab in treating lymphoma? – Elizabeth Budde, MD 2023 reviews new therapies By Elizabeth Budde, Md, PhD…
Odronextamab: ASH 2022 Won Seog Kim MD Prespecified Analysis ELM-2 in DLBCL By Won Seog Kim, MD How can Odronextamab…
iFrame is not supported! Odronextamab: ASH 2022 Won Seog Kim MD Prespecified Analysis ELM-2 in DLBCL By Won Seog Kim,…
Odronextamab: ASH 2022 Won Seog Kim MD Prespecified Analysis ELM-2 in DLBCL By Won Seog Kim, MD How can Odronextamab…
Liso-cel: ASH 2022 Jeremy Abramson vs. SOC SCT and ASCT in RR LBCL By Jeremy Abramson, MD What did the…
iFrame is not supported! Liso-cel: ASH 2022 Jeremy Abramson vs. SOC SCT and ASCT in RR LBCL By Jeremy Abramson,…
Liso-cel: ASH 2022 Jeremy Abramson vs. SOC SCT and ASCT in RR LBCL By Jeremy Abramson, MD What did the…
Pembro: ASH 2022 Mwanasha Merrill Addition After Auto-SCT T-Cell NHL By Mwanasha Merrill, MD How can Pembro (MK-3475) help patients…
iFrame is not supported! Pembro: ASH 2022 Mwanasha Merrill Addition After Auto-SCT T-Cell NHL By Mwanasha Merrill, MD How can…
Pembro: ASH 2022 Mwanasha Merrill Addition After Auto-SCT T-Cell NHL By Mwanasha Merrill, MD How can Pembro (MK-3475) help patients…
Liso-cel: ASH 2022 Data From the Outreach Study By Yuliya Linhares, MD How can Liso-Cell (Lisocabtagene Maraleucel) help patients with…
iFrame is not supported! Liso-cel: ASH 2022 Data From the Outreach Study By Yuliya Linhares, MD How can Liso-Cell (Lisocabtagene…
Liso-cel: ASH 2022 Data From the Outreach Study By Yuliya Linhares, MD How can Liso-Cell (Lisocabtagene Maraleucel) help patients with…
Polatuzumab-Rituximab: RR DLBCL Ariel Perez ASH 2022 Second-Line Therapy By Ariel Perez Perez, MD What did the combination of Polatuzumab-Rituximab…
iFrame is not supported! Polatuzumab-Rituximab: RR DLBCL Ariel Perez ASH 2022 Second-Line Therapy By Ariel Perez Perez, MD What did…
Polatuzumab-Rituximab: RR DLBCL Ariel Perez ASH 2022 Second-Line Therapy By Ariel Perez Perez, MD What did the combination of Polatuzumab-Rituximab…
iFrame is not supported! Axi-cel: Zuma 7 was a randomized phase three study By Armin Ghobadi, MD Zuma 7 was…
Axi-cel: Zuma 7 was a randomized phase 3 study By Armin Ghobadi, MD Zuma 7 was a randomized phase three…
iFrame is not supported! Axicabtagene Ciloleucel (Axi-Cel) Large B-Cell Lymphoma (R/R LBCL): 2-Year Follow-up of ZUMA-1 Cohort 6 By Olalekan…
Axicabtagene Ciloleucel (Axi-Cel) Large B-Cell Lymphoma (R/R LBCL): 2-Year Follow-up of ZUMA-1 Cohort 6 By Olalekan Oluwole, MD, MPH, MBBS…
iFrame is not supported! Lisocabtagene Maraleucel has been approved by the FDA for the second-line treatment of large B cell…
Lisocabtagene Maraleucel has been approved by the FDA for the second-line treatment of large B cell lymphoma LBCL Lisocabtagene Maraleucel…
For the GRACE Blood Cancer Video Library, Dr. Joshua Brody, Associate Professor of Hematology and Medical Oncology, Associate Professor of…
For the GRACE Blood Cancer Video Library, Dr. Joshua Brody, Associate Professor of Hematology and Medical Oncology, Associate Professor of…
For the GRACE Blood Cancer Video Library, Dr. Aaron Goodman, Associate Professor of Medicine Hematology/Oncology, at Moores Cancer Center, UC…
For the GRACE Blood Cancer Video Library, Dr. Aaron Goodman, Associate Professor of Medicine Hematology/Oncology, at Moores Cancer Center, UC…
For the GRACE Blood Cancer Video Library, Dr. Aaron Goodman, Associate Professor of Medicine Hematology/Oncology, at Moores Cancer Center, UC…
For the GRACE Blood Cancer Video Library, Dr. Aaron Goodman, Associate Professor of Medicine Hematology/Oncology, at Moores Cancer Center, UC…
For the GRACE Blood Cancer Video Library, joining us is Dr. Marco Ruiz, M.D., MPH, FACP, FIDSA, Chief of HIV…
For the GRACE Blood Cancer Video Library, joining us is Dr. Marco Ruiz, M.D., MPH, FACP, FIDSA, Chief of HIV…
For the GRACE Blood Cancer Video Library, joining us is Dr. Marco Ruiz, M.D., MPH, FACP, FIDSA, Chief of HIV…
Christiane Querfeld, M.D., Ph.D., Director, Cutaneous Lymphoma Program, City of Hope. In this video, she speaks about the AACR 2022…
Christiane Querfeld, M.D., Ph.D., Director, Cutaneous Lymphoma Program, City of Hope. In this video, she speaks about the AACR 2022…
Stefano Luminari, MD, Department of Surgery, Medicine, Dentistry and Morphological Sciences with interest in Transplantation, Oncology and Regenerative Medicine at…
Stefano Luminari, MD, Department of Surgery, Medicine, Dentistry and Morphological Sciences with interest in Transplantation, Oncology and Regenerative Medicine at…
Brad S. Kahl, MD, Professor of Medicine, Division of Oncology, Washington University School of Medicine in St. Louis speaks about…
Brad S. Kahl, MD, Professor of Medicine, Division of Oncology, Washington University School of Medicine in St. Louis speaks about…
Mahmoud Elsawy, MD, MSc Assistant Professor, Division of Hematology, Dalhousie University. Medical Director of IEC Therapy Program, QEII Health Sciences…
Mahmoud Elsawy, MD, MSc Assistant Professor, Division of Hematology, Dalhousie University. Medical Director of IEC Therapy Program, QEII Health Sciences…
Dr. Med. Prof. Martin Dreyling, PhD, Department of Medicine III, LMU Hospital speaks about ASH 2021 Abstract – 383 R-High…
Dr. Med. Prof. Martin Dreyling, PhD, Department of Medicine III, LMU Hospital speaks about ASH 2021 Abstract – 383 R-High…
Yael Cohen, MD from Tel-Aviv Sourasky (Ichilov) Medical Center, and Sackler School of Medicine, Tel Aviv University speaks about the…
Yael Cohen, MD from Tel-Aviv Sourasky (Ichilov) Medical Center, and Sackler School of Medicine, Tel Aviv University speaks about the…
Elizabeth Lihua Budde, MD, Ph.D. Associate Professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation at the City…
Elizabeth Lihua Budde, MD, Ph.D. Associate Professor, Division of Lymphoma, Department of Hematology and; Hematopoietic Cell Transplantation at the City…
James H. Essell, MD, is a renowned expert on blood and marrow stem cell transplants and is a medical oncologist,…
James H. Essell, MD, is a renowned expert on blood and marrow stem cell transplants and is a medical oncologist,…
Ellen Kim, MD, Medical Director, Dermatology Clinic, Perelman Center for Advanced Medicine, Professor of Dermatology at the Hospital of the…
Sudipto Mukherjee, MD, MPH, Ph.D., Director of Rare Cancers and Blood Diseases, at the Cleveland Clinic speaks about the Epidemiology…
Sudipto Mukherjee, MD, MPH, Ph.D., Director of Rare Cancers and Blood Diseases, at the Cleveland Clinic speaks about the Epidemiology…
Professor Gilles Salles from Memorial Sloan Kettering Cancer Center speaks about the ASCO 2021 Abstract – Long-term analyses from L-MIND,…
Ellen Kim, MD, Medical Director, Dermatology Clinic, Perelman Center for Advanced Medicine, Professor of Dermatology at the Hospital of the…
Professor Gilles Salles from Memorial Sloan Kettering Cancer Center speaks about the ASCO 2021 Abstract – Long-term analyses from L-MIND,…
Grzegorz S. Nowakowski, MD from the Mayo Clinic speaks about Incyte and MorphoSys Announce First Patient Dosed in Phase 3…
Julio Chavez, MD from Moffitts Cancer Center & Research Institute speaks about U.S. FDA Approves Yescarta® for Relapsed or Refractory…
Zhen Han, assistant research professor at City of Hope, and Christiane Querfeld, MD, Ph.D., director of the Cutaneous Lymphoma Program…
John Baird, MD, Fellow in Hematology/Medical Oncology at Stanford Cancer Center speaks about the Retrospective Study: Immune Reconstitution And Infectious…
Stephen M. Ansell, MD, Ph.D. from the Mayo Clinic, Rochester speaks about the review: Checkpoint BLOCKade in Lymphoma.Link To Paper…
Andrew M. Evens, DO, MSc from Robert Wood Johnson University Hospital and Rutgers Cancer Institute of New Jersey discusses the…
Andrew M. Evens, DO, MSc from Robert Wood Johnson University Hospital and Rutgers Cancer Institute of New Jersey discusses the…
Frederick Locke, MD of the Moffitt Cancer Center & Research Institute speaks about the ASH 2020 abstract – 1187 Long-Term…
Tycel J. Phillips, MD from Rogel Cancer Center, University of Michigan discusses the ASH 2020 abstract – 338 Phase 2…
Elizabeth Budde, MD Ph.D. of the City of Hope discusses the ASH 2020 abstract – 1142 Preliminary Results of a…
Constantine S. Tam, MD from Peter MacCallum Cancer Centre and St. Vincent’s Hospital and the University of Melbourne discusses the…
Neetu Gupta, Ph.D., MSc, BSc from the Cleveland Clinic speaks about the ASH 2020 abstract – 1447 Unbiased Metabolomic Screening…
Michael Wang, MD from The University of Texas MD Anderson Cancer Center discusses the ASH 2020 abstract – Acalabrutinib Monotherapy…
Christian Buske, MD – Medical Director Comprehensive Cancer Center and Institute of Experimental Cancer Research of the University Hospital of…
Elly Lugtenburg, MD, Ph.D. from the Erasmus MC Cancer Institute discusses Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell…
Michael Wang, MD, ZUMA-2 Lead Investigator, and Professor at The University of Texas MD Anderson Cancer Center speaks to us…
For the GRACE Blood Cancer Video Library, Dr. Joshua Brody, Assistant Professor of Medicine, Hematology and Medical Oncology and Director…
For the GRACE Blood Cancer Video Library, Dr. Marco Ruiz, Medical Oncologist in Hematologic Cancers specializing in leukemia, lymphoma, Myelodysplastic…
For the GRACE Blood Cancer Video Library, Dr. Marco Ruiz, Medical Oncologist in Hematologic Cancers specializing in leukemia, lymphoma, Myelodysplastic…
For the GRACE Blood Cancer Video Library, Dr. Marco Ruiz, Medical Oncologist in Hematologic Cancers specializing in leukemia, lymphoma, Myelodysplastic…
For the GRACE Blood Cancer Video Library, Dr. Joshua Brody, Assistant Professor of Medicine, Hematology and Medical Oncology and Director…
Michael Wang, MD from MD Anderson discusses a paper from Nature entitled Durable response with single-agent acalabrutinib in patients with…
Daniel Persky, MD @UAZCance #ASCO20 Positron Emission Tomography–Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup…
Theresa Deisher PhD at AVM Biotechnology discusses The WWRD Study: AVM0703 for Treatment of Leukemia or Lymphoma Description in detail:…
Senthil Damodaran, MD of MD Anderson shares his final thoughts on the Phase II study of copanlisib in patients with…
Senthil Damodaran, MD of MD Anderson talks about the common questions he receives about the Phase II study of copanlisib…
Senthil Damodaran, MD of MD Anderson explains the Phase II study of copanlisib in patients with tumors with PIK3CA mutations…
Melissa Johnson, MD, Associate Director, Lung Cancer Research and Drug Development, Sarah Cannon Research Institute at Tennessee Oncology discusses CX-2029,…
Melissa Johnson, MD, Associate Director, Lung Cancer Research and Drug Development, Sarah Cannon Research Institute at Tennessee Oncology discusses CX-2029,…
Oscar Mesa, MD, MSC, Global Director, Health Economics, outcomes research and Market Access Critical care – Mallinckrodt discusses Mallinckrodt and…
Oscar Mesa, MD, MSC, Global Director, Health Economics, outcomes research and Market Access Critical care – Mallinckrodt discusses Mallinckrodt and…
Oscar Mesa, MD, MSC, Global Director, Health Economics, outcomes research and Market Access Critical care – Mallinckrodt discusses Mallinckrodt and…
Earn CME: https://www.naccme.com/program/20-hemcovid-2 In this webcast, Drs. Joseph R. Mikhael and John P. Leonard discuss challenges faced by US healthcare…
Earn CME: https://www.naccme.com/program/19-lm-15 In this webcast from the ‘New and Emerging Agents in MCL’ symposium during the 2019 Lymphoma &…
Earn CME: https://www.naccme.com/program/19-lm-14 In this webcast from the ‘Revolutionizing the R/R DLBCL Treatment Paradigm: Innovative, Strategic & Targeted Approaches’ symposium…
Earn CME: https://www.naccme.com/program/19-lm-13 In this webcast from the ‘Treatment for Marginal Zone Lymphoma: Should it be Different from FL?’ symposium…
Earn CME: https://www.naccme.com/program/19-lm-13 In this webcast from the ‘Treatment for Marginal Zone Lymphoma: Should it be Different from FL?’ symposium…
Earn CME: https://www.naccme.com/program/19-lm-11 In this webcast from the ‘Moving Forward in the Treatment of Relapsed/Refractory Follicular Lymphoma: Understanding the PI3K…
Earn CME: https://www.naccme.com/program/19-lm-11 In this webcast from the ‘Moving Forward in the Treatment of Relapsed/Refractory Follicular Lymphoma: Understanding the PI3K…
Earn CME: https://www.naccme.com/program/19-lm-11 In this webcast from the ‘Moving Forward in the Treatment of Relapsed/Refractory Follicular Lymphoma: Understanding the PI3K…
Herbert Eradat, MD, MS @dgsomucla Associate Clinical Professor UCLE Lymphoma Program UCLA BMT & CAR-T Cell Program, David Geffen School…
Earn CME: https://naccme.com/program/7334 In this presentation from the ‘Keeping Up With CAR T-cell Therapies in B-Cell Lymphomas’ symposium at the…
Earn CME: https://www.naccme.com/program/7333 In this presentation from the ‘Persistent Challenges in the Management of Follicular Lymphoma’ symposium at the 2019…
Earn CME: https://naccme.com/program/7333 In this presentation from the ‘Persistent Challenges in the Management of Follicular Lymphoma’ symposium at the 2019…
Earn CME: https://naccme.com/program/7334 In this presentation from the ‘Keeping Up With CAR T-cell Therapies in B-Cell Lymphomas’ symposium at the…
Earn CME: https://www.naccme.com/program/7332 In this presentation from the ‘Confronting the Challenges of Peripheral T-Cell Lymphoma: Genomic Profiling and the Future…
ASH 2016 Page 5 Update on CAR-T Cell Therapy in Lymphoma
ASH 2016 Page 8 Leonard New Data for Mantel Cell and T-Cell Lymphoma Patients
ASH 2016 Page 7 Leonard Follicular Lymphoma Treatment Update
ASH 2016 Page 6 Leonard Update on Diffuse Large B Cell Lymphoma Treatments
Lori A. Leslie, MD, Hematologist-Oncologist, Lymphoma Department, John Theurer Cancer Center, Hackensack Meridian Health shares details on the CLL14 trial…
Lori A. Leslie, MD, Hematologist-Oncologist, Lymphoma Department, John Theurer Cancer Center, Hackensack Meridian Health considers how CAR-T cell therapy may…
Lori A. Leslie, MD, Hematologist-Oncologist, Lymphoma Department, John Theurer Cancer Center, Hackensack Meridian Health explains the results of the umbralisib…
Andre Goy, MD, Chairman and Director of the John Theurer Cancer Center (JTCC) at Hackensack University Medical Center and Chief…
Andre Goy, MD, Chairman and Director of the John Theurer Cancer Center (JTCC) at Hackensack University Medical Center and Chief…
Andre Goy, MD, Chairman and Director of the John Theurer Cancer Center (JTCC) at Hackensack University Medical Center and Chief…
What therapy should we use for DLBCL in 2016
Are vaccines dead in lymphoma and CLL
Are all DLBCL made equally
Josh Brody MD @joshuabrodyMD Of Icahn School of Medicine at Mount Sinai Discusses New PI3K-Delta Inhibitor Umbralisib: Greater Then 50%…
David Andorsky MD Of US Oncology Research Discusses MAGNIFY Study: Phase 3 Study Of Lenalidomide (Revlimid) Plus Rituximab (Rituxan) Followed…
Tsering Lama Tamang, M.D. Division of Hematology and Oncology, University of California, Irvine Discusses Data On The ALLIANCE Trial. At…
Tsering Lama Tamang, M.D. Division of Hematology and Oncology, University of California, Irvine Discusses ALLIANCE Trial & Low MRD. At…
Tsering Lama Tamang, M.D. Division of Hematology and Oncology, University of California, Irvine Discusses ALLIANCE Trial & Its Effect On…
Elizabeth Brem, M.D. HS Clinical Assistant Professor at Chao Comprehensive Cancer Center Discusses Where We Are In Our Understanding Of…
Elizabeth Brem, M.D. HS Clinical Assistant Professor at Chao Comprehensive Cancer Center Discusses Whats Next In DLBCL. At MOASC on…
Elizabeth Brem, M.D. HS Clinical Assistant Professor at Chao Comprehensive Cancer Center Discusses Next Steps In R-CHOP Studies. At MOASC…
Elizabeth Brem, M.D. HS Clinical Assistant Professor at Chao Comprehensive Cancer Center Discusses Two Abstracts That Could Effect Clinicians. At…
Elizabeth Brem, M.D. HS Clinical Assistant Professor at Chao Comprehensive Cancer Center Discusses Four Abstracts Presented At MOASC. At MOASC…
Robert Rifkin, MD, Hematologist/Oncologist, Associate Chair, US Oncology Hematology Research, Rocky Mountain Cancer Centers, discusses Can A Rituximab Biosimilar Replace…
Swaminathan P. Iyer, MD, Professor, Department of Lymphoma and Myeloma, Division of Cancer Medicine Division, MD Anderson Cancer Center, discusses…
Tatyana Feldman, MD, Hematology & Oncology, Hackensack University Medical Center, John Theurer Cancer Center, discusses Exciting Studies From ASH 2018…
Tatyana Feldman, MD, Hematology & Oncology, Hackensack University Medical Center, John Theurer Cancer Center, discusses ECHELON-2 Study. At The 60th…
Jasmine Zain, MD, Associate Clinical Professor of Hematology & Hematopoietic Cell Transplantation, Director, T Cell Lymphoma Program, City of Hope,…
Jasmine Zain, MD, Associate Clinical Professor of Hematology & Hematopoietic Cell Transplantation, Director, T Cell Lymphoma Program, City of Hope,…
Frederick Locke, MD, Program Co-Leader, Immunology Moffitt Cancer Center, discusses How To Integrate CAR-T With Stem Cell Transplant. At The…
Andre Goy, MD, Chairman and Director of John Theurer Cancer Center, Chief of the Division of Lymphoma, Hackensack University Medical…
Julie Vose, MD, Professor, Internal Medicine Division of Oncology & Hematology University of Nebraska Medical Center, Discusses Improvements Made In…
Jasmine Zain, MD, Associate Clinical Professor of Hematology & Hematopoietic Cell Transplantation, Director, T cell Lymphoma Program, City of Hope,…
Andre Goy, MD, Chairman and Director of John Theurer Cancer Center, Chief of the Division of Lymphoma, Hackensack University Medical…
Tatyana Feldman, MD, Hematology & Oncology, Hackensack University Medical Center, John Theurer Cancer Center, discusses Improvements In The Treatment Of…
Lorenz Trumper, MD, Professor of Internal Medicine and Chairman of the Department of Hematology and Oncology, Georg August University of…
Jeff Sharman, MD, Director of Research, Willamette Valley Cancer Institute, Medical Director of Hematology Research, The US Oncology Network, discusses…
Swaminathan P. Iyer, MD, Professor, Department of Lymphoma and Myeloma, Division of Cancer Medicine Division, MD Anderson Cancer Center, discusses…
Sattva Neelapu, MD, Department of Lymphoma and Myeloma, Division of Cancer Medicines, MD Anderson Cancer Center, discusses The Use Of…
Jasmine Zain, MD, Associate Clinical Professor of Hematology & Hematopoietic Cell Transplantation, Director, T cell Lymphoma Program, City of Hope,…
Andre Goy, MD Chairman and Director of John Theurer Cancer Center, Chief of the Division of Lymphoma, Hackensack University Medical…
Jasmine Zain, MD, Associate Clinical Professor of Hematology & Hematopoietic Cell Transplantation, Director, T cell Lymphoma Program, City of Hope,…
Andre Goy, MD Chairman and Director of John Theurer Cancer Center, Chief of the Division of Lymphoma, Hackensack University Medical…
Julie Vose, MD Professor Internal Medicine Division of Oncology & Hematology University of Nebraska Medical Center, discusses Does Polatuzumab Improve…
Sattva Neelapu, MD Department of Lymphoma and Myeloma, Division of Cancer Medicines, MD Anderson Cancer Center, discusses The Future Of…
Lorenz Trumper, MD Professor of Internal Medicine and Chairman of the Department of Hematology and Oncology, Georg August University of…
Swaminathan P. Iyer, MD Professor, Department of Lymphoma and Myeloma, Division of Cancer Medicine Division, MD Anderson Cancer Center, discusses…
Tatyana Feldman, MD Hematology & Oncology, Hackensack University Medical Center, John Theurer Cancer Center, discusses The Unmet Needs In Peripheral…
Lorenz Trumper, MD Professor of Internal Medicine and Chairman of the Department of Hematology and Oncology, Georg August University of…
Julie Vose, MD Professor, Internal Medicine Division of Oncology & Hematology University of Nebraska Medical Center discusses Are CAR-T Therapies…
Swaminathan Padmanabhan Iyer, MD Professor, Department of Lymphoma and Myeloma, MD Anderson Cancer Center discusses Game Changing ECHELON-2 Study For…
Frederick Locke, MD Program Co-Leader, Immunology Moffitt Cancer Center Discusses Using CAR-T Therapies In Leukemia & Lymphoma. At The 60th…
Andre Goy, MD Chairman and Director of John Theurer Cancer Center, Chief of the Division of Lymphoma, Hackensack University Medical…
Elizabeth Budde, MD Assistant Professor in the Department of Hematology & Hematopoietic Cell Transplantation, City of Hope Discusses CAR-T Therapies…
Sattva Neelapu, MD Department of Lymphoma and Myeloma, Division of Cancer Medicines, MD Anderson Cancer Center Discusses ZUMA-1 Two-Year Follow-Up…
Jasmine Zain, MD Associate Clinical Professor of Hematology & Hematopoietic Cell Transplantation, Director, T Cell Lymphoma Program, City of Hope…
Michael Wang, M.D. Professor in the department of Lymphoma & Myeloma at MD Anderson Discusses Metabolic Reprogramming At The 60th…
Michelle Dawson Franchise Head Hematology, US Medical Affairs at AstraZeneca Discusses Acalabrutinib Key Clinical Data At The 60th ASH Annual…
Mohamed Mohty, M.D., PhD Professor of Hematology and head of the Hematology and Cellular Therapy Department at the Saint-Antoine Hospital…
Michael Wang, M.D. Professor in the department of Lymphoma & Myeloma at MD Anderson Discusses Acalabrutinib Trial follow Up At…
Michael Wang, M.D. Professor in the department of Lymphoma & Myeloma at MD Anderson Discusses Acalabrutinib Therapy: Infection Rate &…
Sattva Neelapu, M.D. Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston,…
Sattva Neelapu, M.D. Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston,…
Mohamed Mohty, M.D., PhD Professor of Hematology and head of the Hematology and Cellular Therapy Department at the Saint-Antoine Hospital…
Rajat Bannerji, MD, PhD Associate Professor of Medicine Division of Hematology Oncology Robert Wood Johnson Medical School Rutgers, The State…
Earn CME: https://naccme.com/program/7317 In this presentation from the ‘Evaluating the Role of PI3K Inhibitors in Follicular Lymphoma: Highlighting the Diversity…
Earn CME: https://naccme.com/program/7317 In this presentation from the ‘Evaluating the Role of PI3K Inhibitors in Follicular Lymphoma: Highlighting the Diversity…
Earn CME: https://naccme.com/program/7316 In this presentation from the ‘Surviving and Thriving with B-Cell Malignancies: Surveying an Ever-Evolving Landscape symposium, Dr.…
Earn CME: https://naccme.com/program/7316 In this presentation from the ‘Surviving and Thriving with B-Cell Malignancies: Surveying an Ever-Evolving Landscape symposium, Dr.…
Earn CME: https://naccme.com/program/7315 In this presentation from the ‘CAR-T for Lymphomas: Cultivating a Cure, Controlling a Crisis symposium, Nurse Rita…
Earn CME: https://naccme.com/program/7315 In this presentation from the ‘CAR-T for Lymphomas: Cultivating a Cure, Controlling a Crisis symposium, Dr. Caron…
Earn CME: https://naccme.com/program/7315 In this presentation from the ‘CAR-T for Lymphomas: Cultivating a Cure, Controlling a Crisis symposium, Dr. Caron…
Earn CME: https://naccme.com/program/7309 In this Key Insights activity, Drs. Morton Coleman and John P. Leonard discuss highlights in lymphoma from…
At the 2018 British Oncology Pharmacy Association (BOPA) Annual Symposium, Simon Cheesman, MRPharmS, of University College London, London, UK, presented…
The field of blood cancer therapeutics has seen enormous progression. Here, Steven Rosen, MD, from the City of Hope, Duarte,…
Speaking from the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2018 meeting, held in Nice, France, Bianca Santomasso, MD, PhD, of…
Maintenance therapy options for cutaneous T-cell lymphomas could be improved. Here, Rudolf Stadler, MD, PhD, of the University Medical Center…
Establishing a registry and prognostic index for mycosis fungoides, the most common type of cutaneous T-cell lymphoma (CTCL), and Sézary…
Our understanding of stem cells has improved exponentially since their discovery, transforming our treatment of hematological malignancies and other diseases.…
A novel CD47-blocking checkpoint inhibitor has shown promising interim results in a multicenter Phase I trail for relapsed/refractory mycosis fungoides…
Precision medicine is improving outcomes, toxicity and disease management in trials and routine clinical practice. Anas Younes, MD, from the…
In this session, Thomas Habermann, MD, of the Mayo Clinic, Rochester, MI, chairs a discussion with Bjoern Chapuy, PhD, MD,…
Immunotherapy is at the forefront of research into novel treatments for lymphoma. Here, John Gribben, MD, DSc, FRCP, FRCPath, FMed…
CAR T-cells are a hot topic right now, with huge potential for transforming the treatment of various hematological malignancies, including…
Lymphoma treatment is focusing increasingly on novel agents with specific targets. At the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2018…
CAR T-cells have the potential to revolutionize the field of hematological oncology, however despite impressive efficacy data from CAR T…
Axicabtagene ciloleucel, an anti-CD19 CAR T-cell product, has shown impressive efficacy in diffuse large B-cell lymphoma already. In this video,…
Speaking from the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting held in Houston, TX, John Rossi, MS, from Kite…
Nathan Fowler, MD, of The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the use of minimal residual…
Patients that relapse or are resistant to treatments are classified as high-risk in follicular lymphoma. Here, Nathan Fowler, MD, of…
In this interview, recorded at the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal,…
Speaking from the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal, Andrés Ferreri, MD,…
Dividing patients into subgroups for different therapies can often be quite difficult. In this interview, recorded at the 2018 European…
Martin Hutchings, MD, PhD from Copenhagen University Hospital, Copenhagen, Denmark, discusses current first-line treatment options in Hodgkin lymphoma at the…
Dr Olivier Casasnovas, from the Department of Hematology, Dijon, France, gives an update on data from the Phase III AHL2011…
Data from the exciting iNNOVATE study (NCT02165397) of ibrutinib plus rituximab for patients with Waldenströms macroglobulinemia (WM) were presented at…
“Dr Laurie Sehn, of the BC Cancer Agency, Vancouver, BC, Canada presents: ‘Answering the unmet need in one of the…
Dr Franck Morschhauser, of Centre Hospitalier Universitaire Régional de Lille, Unité GRITA, Lille, France, discusses the question: is RELEVANCE relevant?…
Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Raúl Córdoba, MD, PhD, MS,…
Patients with T-cell leukemias typically have a worse prognosis than those with B-cell malignancies. In this interview, Kimberly Dunsmore, MD,…
Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Raúl Córdoba, MD, PhD, MS,…
In this interview, Raúl Córdoba, MD, PhD, MS, of the Fundacion Jimenez Diaz University Hospital, Madrid, Spain, discusses the problems…
BTK inhibitors like ibrutinib have shown impressive efficacy in treating mantle cell lymphoma (MCL) in the first relapse setting; however,…
BTK inhibition is a popular avenue of treatment research in Waldenström’s macroglobulinemia (WM). In this video, recorded at the 23rd…
Patients with relapsed, transplant ineligible diffuse large B-cell lymphoma (DLBCL) face extremely poor outcomes. In this video, recorded at the…
Speaking from the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden, Simon Rule, MD, of…
Mantle cell lymphoma (MCL) outcomes have improved in recent years as a result of an influx of improved treatments, including…
Follicular lymphoma treatments are improving; however, there are subgroups of patients who still have poor outcomes. Here, Marek Trneny, MD,…
In relapsed/refractory diffuse large B-cell lymphoma (DLBCL), response rates are poor for salvage treatments and autologous stem cell transplants. Here,…
Chemotherapy is ineffective against a certain subset of diffuse large B-cell lymphoma (DLBCL) types. In this video, recorded at the…
Cutting-edge trial data in the field of lymphoma was presented at the American Society of Oncology (ASCO) 2018 Annual Meeting…
Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting in Chicago, IL, Nathan Fowler, MD, of the MD…
Results of the Phase III RELEVANCE trial (NCT01476787) of rituximab-lenalidomide for untreated follicular lymphoma were presented at the American Society…
Currently, CAR T-cell products are primarily tested in the relapsed setting. However, bringing these novel agents to patients earlier in…
CAR T-cell monotherapies have produced promising results; however, the duration of remission needs to be optimized. Here, Jeremy Abramson, MD,…
CAR T-cells represent an exciting new treatment frontier across a variety of blood cancers. We interviewed David Maloney, MD, PhD,…
BTK inhibitors have seen success in treating various hematological malignancies, and their approval has been extended to mantle cell lymphoma…
Ramon Garcia-Sanz, MD, PhD from the University Hospital of Salamanca, Salamanca, Spain, shares exciting data in Waldenströms macroglobulinemia (WM) from…
Stem cell transplants are one of the most well-studied and effective therapies for blood cancers. In this video, Anna Sureda,…
While the current frontline ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) regimen for treating advanced-stage Hodgkin lymphoma is effective with manageable side…
In this interview with Arjan Diepstra, PhD, from the University of Groningen, Groningen, Netherlands, speaking from the 23rd congress of…
The tumor microenvironment is an important therapeutic consideration. Here, Stephen Devereux, FRCP, FRCPath, PhD, of Kings College Hospital NHS Foundation…
CAR T-cell therapy has been established as an effective treatment option for a range of hematological cancers. In this video,…
While treatment for follicular lymphoma (FL) has improved in recent years, allowing most patients to have good outcomes, there remains…
The RELEVANCE study (NCT01476787) looks at the ‘R-squared’ regimen that combines lenalidomide and rituximab for the treatment of follicular lymphoma.…
In this video, Raul Cordoba, MD, PhD, outlines the pre-clinical studies that are occurring at the Fundacion Jimenez Diaz University…
The Checkmate 205 study (NCT02181738) is looking at nivolumab in previously treated and newly diagnosed patients with classical Hodgkin lymphoma.…
Difficult multidisciplinary team decisions occur within follicular lymphoma (FL) due to the heterogeneity that exists within the disease. In this…